USPTO serial 79399168
AB ANALITICA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 9, 2025
- Examiner
- LOBO, DEBORAH E
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with AB ANALITICA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Robert S. Broder
Robert S. Broder Collard & Roe, P.C.1077 Northern Blvd.Roslyn, NY 11576United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Gastrointestinal treatment preparations; medicines for the treatment of gastrointestinal diseases; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; milk sugar for pharmaceutical purposes; vaccines; diagnostic preparations for medical purposes; diagnostic preparations and substances for medical purposes; clinical medical reagents; clinical diagnostic reagents for medical use; diagnostic agents for medical use; diagnostic substances for medical use; diagnostic agents for pharmaceutical use; biological indicators for medical diagnosis; pregnancy testing preparations; in vitro diagnostic preparations for medical use; chemical reagents for in-vitro veterinary purposes for use by veterinary laboratories; chemical reagents for in-vitro medical purposes for use by medical laboratories; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical compounds for treating cancer; male fertility test kits; reagents for medical use; diagnostic reagents for medical use; biological reagents for medical use; chemical reagents for medical use; reagents for use with analyzers for medical purposes; diagnostic chemical reagents for medical use; reagents for use in analysis for medical purposes; chemical test reagents for medical purposes; diagnostic biomarker reagents for medical purposes; reagents for use in diagnostic tests for medical purposes; reagents for microbiological analysis for medical purposes; chemical reagents for medical or veterinary purposes; reagents for use in medical genetic testing; reagents for use in diagnostic tests for veterinary purposes; reagents for analytical purposes for medical purposes; medical diagnostic reagents and assays for testing of body fluids; reagents for use in diagnostic pregnancy tests; reagents for use in analysis for veterinary purposes; culture media for medical use; reagents for use in veterinary genetic testing; biochemical preparations for medical use; preparations for detecting mutation in prion genes for medical purposes; preparations for detecting genetic predispositions for medical purposes; glucose for medical purposes; glucose dietary supplements; glucose for use as an additive to foods for medical purposes; pharmaceutical preparations for the prevention of disorders of the metabolic system; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations for treating gastrointestinal disorders; antivirals in the nature of DNA synthesis inhibitors; chemical preparations for use in DNA analysis for medical purposes; dietary supplements and dietetic preparations; diagnostic preparations for medical or veterinary purposes. | ACTIVE | — |
| 042 | Pharmaceutical drug development services; research on the subject of pharmaceuticals; scientific research in the field of pharmacy; medical and pharmacological research services; medical research laboratory services; testing of pharmaceuticals; research and development of vaccines and medicines; design and development of medical diagnostic apparatus; scientific research for medical purposes in the area of cancerous diseases; research and development in the field of diagnostic preparations; genetic research; scientific research in the field of genetics and genetic engineering; scientific research relating to genetics; laboratory research in the field of gene expression; DNA screening for scientific research purposes; laboratory research services, namely, DNA testing services to determine paternity; testing for new product development; design and testing for new product development; testing of new product designs for others; new product design; quality control for others; design and testing for new product development; design and testing of new products; scientific research and development; pharmaceutical research and development; research and development in the pharmaceutical and biotechnology fields; scientific research and development services; research and development of computer software; development and testing of chemical production methods; quality control of manufactured goods; design and development of computer hardware; software design and development; design of instruments; design services relating to data processing tools; design and development of diagnostic apparatus; product research and development; computer design research; development of pharmaceutical preparations and medicines; scientific investigations for medical purposes; biological research, clinical research and medical research; research in the field of pharmacogenetics; laboratory testing of materials; laboratory services for medical research; research and development in the field of microorganisms and cells; research relating to molecular sciences; research and development in the field of biotechnology; bacteriological research; toxicology testing for research purposes; biological research and analysis; physics research; chemical research; scientific research relating to biology; biological research laboratory services; research and development services in the field of immunohistology; provision of medical research services; leasing of scientific laboratory research instruments; computer rental; software development, programming and implementation; data mining; computer software design and updating; preparation of technical reports in the pharmaceutical field; preparation of scientific reports in the pharmaceutical field; technological research in the pharmaceutical field; scientific analysis in the field of molecular biology; biological research. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by AB ANALITICA S.r.l.
- Other trademarks owned by AB ANALITICA S.r.l.
- Other trademarks owned by AB ANALITICA S.r.l.
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named AB ANALITICA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 23, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 3, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 3, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Mar 9, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Dec 18, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Dec 9, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Dec 9, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 3, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 3, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Oct 21, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 21, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 15, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 22, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 22, 2025 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 22, 2025 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 22, 2025 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 22, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 9, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 9, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 9, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 5, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 5, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 5, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 2, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 11, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 11, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 9, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 8, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 28, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 12, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 12, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 8, 2024 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Jul 4, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |